MedPath

Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia

Phase 4
Completed
Conditions
Postoperative Residual Curarization
Residual Neuromuscular Block
Interventions
Registration Number
NCT01651572
Lead Sponsor
Azienda Ospedaliera di Padova
Brief Summary

The purpose of this study is to determine the incidence of post-operative residual curarization in our patients and to determine if Cisatracurium and Rocuronium behave differently from each other in terms of residual curarization.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • general anaesthesia with need to use of neuromuscular-blocking agents
  • awakening and extubation of the patient in the operating room and permanence in the PACU for at least 60 minutes
  • age 18-80
  • surgical operations lasting at least 1 hour
  • ASA class I-III
  • possibility to apply TOF-monitoring with thumb-acceleromyography
  • women of childbearing age not using contraceptives
  • women of childbearing age using contraceptives
Exclusion Criteria
  • subjects unable to give a valid consent
  • patients in emergency situations
  • patients not awakened and not extubated in the operating room
  • age above 80 years or under 18 years
  • surgical operations lasting less than an hour
  • ASA class IV
  • impossibility to apply and/or perform TOF-monitoring
  • neuromuscular diseases
  • intake of therapies interfering with the neuromuscular function
  • patients having contraindications for either studied drug
  • pregnant women
  • women who are breast-feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CisatracuriumCisatracuriumInduction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl. Cisatracurium (Nimbex): * initial dose: 0.2 mg/kg * maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches) At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg. Patients will be extubated with a TOF-Ratio of at least 0.90.
RocuroniumRocuroniumInduction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl Rocuronium (Esmeron): * initial dose: 0.6 mg/kg * maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches) At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg. Patients will be extubated with a TOF-Ratio of at least 0.90.
Primary Outcome Measures
NameTimeMethod
Incidence of PORCParticipants will be followed for the duration of their stay in the post-anaesthesia care unit (PACU), an expected average of 60 minutes.

To determine the incidence of post-operative residual curarization in our operating rooms, comparing two different neuromuscular-blocking agents: Cisatracurium and Rocuronium.

The primary endpoint is quantified with TOF-Ratio, determined with the device TOF-Watch SX (Organon, Netherlands). A TOF-Ratio\<0.90 defines PORC.

Three clinical parameters (head-tilt for 5 seconds, ability to swallow, presence of diplopia) are also evaluated.

TOF-Ratios, as long as the above-mentioned clinical parameters are determined and evaluated at 15, 30 and 60 minutes after extubation of the patient.

Secondary Outcome Measures
NameTimeMethod
Incidence of PORC - comparison between Cisatracurium and RocuroniumParticipants will be followed for the duration of their stay in the post-anaesthesia care unit (PACU), an expected average of 60 minutes.

Trial Locations

Locations (1)

Azienda Ospedaliera di Padova

🇮🇹

Padova, Italy

© Copyright 2025. All Rights Reserved by MedPath